Pembrolizumab efficacy in a <scp>tumor mutation burden</scp>‐high glioblastoma patient: A case study and implications for precision oncology
A glioblastoma (GBM) patient with a high tumor mutation burden (TMB-high) and mismatch repair deficiency (dMMR) exhibited a significant response to pembrolizumab, an immune checkpoint inhibitor (ICI), despite prior treatment with temozolomide (TMZ), known to induce hypermutation and potential resistance to ICIs. The rapid disease progression, indicated by 80% Ki67 positivity, was markedly countered by the positive outcome of pembrolizumab treatment. This case challenges traditional GBM treatment paradigms, demonstrating the potential of precision oncology in patients with significant TMB and dMMR, and underscores the importance of comprehensive genomic profiling in guiding clinical decisions in GBM management.
Authors
- Akihiro Nishiyama (ORCID: https://orcid.org/0000-0002-4805-9787)
- Chie Shimaguchi
- Atsushi Tajima (ORCID: https://orcid.org/0000-0001-6808-5491)
- Masashi Kinoshita (ORCID: https://orcid.org/0000-0002-2148-8231)
- Mitsutoshi Nakada (ORCID: https://orcid.org/0000-0001-9419-6101)
- Hiroshi Kotani (ORCID: https://orcid.org/0000-0002-6001-0636)
- Shinji Takeuchi (ORCID: https://orcid.org/0000-0002-3779-1454)
- Hiroyuki Sakaguchi
- Koushiro Ohtsubo (ORCID: https://orcid.org/0000-0002-4490-4306)
- Keishi Mizuguchi (ORCID: https://orcid.org/0009-0004-2432-5421)
- Atsushi Watanabe (ORCID: https://orcid.org/0000-0001-9143-3079)
- Hiroko Ikeda (ORCID: https://orcid.org/0000-0001-7105-6376)
- Tomoko Sekiya
- Kaname Yamashita
- Shigeki Sato (ORCID: https://orcid.org/0009-0001-7753-4559)
Institutions
- Kanazawa University (JP)
- Kanazawa University Hospital (JP)
- Kanazawa Medical University Hospital (JP)
Publication Details
- Journal
- Cancer Science
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1111/cas.16370
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28